| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL25 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IL-25抗体的3篇代表性文献的简要概括：
1. **"Anti-IL-25 monoclonal antibody ameliorates experimental asthma via restoration of Th2/Treg balance"**
- **作者**: Smith A, et al.
- **摘要**: 研究通过抑制IL-25信号，在小鼠哮喘模型中减少Th2炎症反应，恢复调节性T细胞(Treg)功能，显著缓解气道高反应性和黏液分泌。
2. **"IL-25 blockade attenuates intestinal inflammation and fibrosis in colitis models"**
- **作者**: Chen L, et al.
- **摘要**: 实验表明，使用IL-25中和抗体可抑制肠道ILC2细胞活化，降低促炎因子IL-13和IL-5水平，减轻小鼠结肠炎病理损伤及纤维化进程。
3. **"Targeting IL-25 in atopic dermatitis: a preclinical study of antibody-based therapy"**
- **作者**: Kim Y, et al.
- **摘要**: 在特应性皮炎小鼠模型中，抗IL-25抗体通过抑制IL-33/TSLP通路，减少皮肤嗜酸性粒细胞浸润和表皮增厚，提示其治疗慢性皮肤炎症的潜力。
(注：上述文献为示例性内容，实际引用需根据具体研究补充真实信息。)
Interleukin-25 (IL-25), a member of the IL-17 cytokine family (specifically IL-17E), is primarily produced by epithelial cells, eosinophils, mast cells, and other immune cells. It plays a critical role in promoting type 2 immune responses, which are associated with allergic inflammation, parasitic infections, and tissue repair. IL-25 binds to a heterodimeric receptor complex (IL-17RA/IL-17RB) on target cells, activating downstream signaling pathways like NF-κB and STAT3. leading to the production of type 2 cytokines (e.g., IL-4. IL-5. IL-13) and recruitment of eosinophils and basophils. Dysregulated IL-25 signaling is implicated in asthma, atopic dermatitis, and autoimmune disorders.
IL-25 antibodies are therapeutic or research tools designed to neutralize IL-25 activity. Monoclonal antibodies targeting IL-25 or its receptors aim to block this pathway, thereby reducing type 2 inflammation. Preclinical studies show their potential in alleviating symptoms of allergic diseases and autoimmune conditions. For example, anti-IL-25 antibodies have demonstrated efficacy in reducing airway hyperresponsiveness in asthma models and mitigating skin inflammation in atopic dermatitis. Clinical trials are ongoing to evaluate their safety and therapeutic potential in humans. These antibodies represent a promising strategy for precision immunotherapy, offering targeted modulation of pathogenic immune responses with fewer systemic side effects compared to broad immunosuppressants.
×
